

Full g:Profiler Results: Control, Hypoxia (3) vs. Control, Normoxia (3)

| Source | Term | Adj. P | -log ₁₀ Adj. P | Sig. Genes in Term | | |
|-----------------------------|---|--------------|---------------------------|---|---|---|
| GO: Molecular Function | monosaccharide binding | 2.74 E-07 | 6.5624 | ALDOA EGLN1 GPI GYS1 | LMAN1 P4HA2 PFKL | PFKP PLOD2 TALDO1 |
| | intramolecular oxidoreductase activity, interconverting aldoses and ketoses | 0.0003 | 3.5110 | GNPDA1 GPI | MPI | TPI1 |
| | carbohydrate binding | 0.0012 | 2.8872 | ALDOA EGLN1 GPI GYS1 | LMAN1 P4HA2 PFKL PFKP | PLOD2 PPP1R3G STBD1 TALDO1 |
| | oxidoreductase activity | 0.0013 | 2.8668 | ADH5 ALKBHS APEX1 EGLN1 ERO1A FTH1 GAPDH | HSD17B10 KIAA1191 LDHA LOX NQO1 P4HA2 P4HB | PGK1 PLOD2 RSAD1 SRXN1 TXNRD1 VKORC1 |
| | intramolecular oxidoreductase activity | 0.0015 | 2.8113 | ERO1A GNPDA1 | GPI MPI | P4HB TPI1 |
| | glucose catabolic process to pyruvate | 4.17 E-14 | 13.3793 | ALDOA ALDOC ENO1 ENO2 | GAPDH GPI PFKL PFKP | PGAM1 PGK1 TPI1 |
| | canonical glycolysis | 4.17 E-14 | 13.3793 | ALDOA ALDOC ENO1 ENO2 | GAPDH GPI PFKL PFKP | PGAM1 PGK1 TPI1 |
| | NADH regeneration | 4.17 E-14 | 13.3793 | ALDOA ALDOC ENO1 ENO2 | GAPDH GPI PFKL PFKP | PGAM1 PGK1 TPI1 |
| | glycolytic process through fructose-6-phosphate | 7.19 E-14 | 13.1434 | ALDOA ALDOC ENO1 ENO2 | GAPDH GPI PFKL PFKP | PGAM1 PGK1 TPI1 |
| | glycolytic process through glucose-6-phosphate | 7.19 E-14 | 13.1434 | ALDOA ALDOC ENO1 ENO2 | GAPDH GPI PFKL PFKP | PGAM1 PGK1 TPI1 |
| GO: Biological Process | cytoplasmic part | 4.64 E-06 | 5.3334 | N=107 | | |
| | cytoplasm | 6.67 E-06 | 5.17577 | N=119 | | |
| | cytosol | 1.85 E-05 | 4.7333 | N=69 | | |
| | extracellular exosome | 0.0001 | 3.8590 | ADH5 ALDOA ALDOC CCT6A CNDP2 ENO1 ENO2 FTH1 GAPDH | LDHA LMAN1 MARCKSL1 MPI MUC1 NDRG1 NEU1 P4HB PFKL | PGM1 PLOD2 PTPRF RAB29 SERPINE1 SLC2A1 SLC3A2 SQSTM1 TALDO1 |
| | | | | | | |
| GO: Cellular Compartment | | | | | | |

| | | | | | | |
|------------------------------|--------|---------|--|---------|----------|----------|
| | | | | GNPDA1 | PFKP | TPI1 |
| | | | | GPI | PGAM1 | TXNRD1 |
| | | | | HSPD1 | PGAM4 | VWA1 |
| | | | | HSPH1 | PGK1 | |
| | | | | ADH5 | LDHA | |
| | | | | ALDOA | LMAN1 | PGM1 |
| | | | | ALDOC | MARCKSL1 | PLOD2 |
| | | | | CCT6A | MPI | PTPRF |
| | | | | CNDP2 | MUC1 | RAB29 |
| | | | | ENO1 | NDRG1 | SERpine1 |
| extracellular vesicle | 0.0001 | 3.7423 | | ENO2 | NEU1 | SLC2A1 |
| | | | | FTH1 | P4HB | SLC3A2 |
| | | | | GAPDH | PFKL | SQSTM1 |
| | | | | GNPDA1 | PFKP | TALDO1 |
| | | | | GPI | PGAM1 | TPI1 |
| | | | | HSPD1 | PGAM4 | TXNRD1 |
| | | | | HSPH1 | PGK1 | VWA1 |
| | | | | ADH5 | GAPDH | PGAM1 |
| Glycolysis / Gluconeogenesis | 6.99 | 14.1556 | | ALDOA | GPI | PGAM4 |
| | E-15 | | | ALDOC | LDHA | PGK1 |
| | | | | ENO1 | PFKL | PGM1 |
| | | | | ENO2 | PFKP | TPI1 |
| | | | | ADH5 | GAPDH | PGAM4 |
| Carbon metabolism | 5.20 | 9.2842 | | ALDOA | GPI | PGK1 |
| | E-10 | | | ALDOC | PFKL | TALDO1 |
| | | | | ENO1 | PFKP | TPI1 |
| | | | | ENO2 | PGAM1 | |
| | | | | ALDOA | GAPDH | PGAM4 |
| KEGG Pathways | 6.23 | 9.2058 | | ALDOC | GPI | PGK1 |
| | E-10 | | | ENO1 | PFKP | TALDO1 |
| | | | | ENO2 | PGAM1 | TPI1 |
| | | | | ALDOA | GAPDH | PGAM4 |
| Biosynthesis of amino acids | 3.13 | 6.5042 | | ALDOC | LDHA | SERpine1 |
| | E-07 | | | ENO1 | PFKL | SLC2A1 |
| | | | | ENO2 | PGK1 | VEGFA |
| | | | | ALDOA | GAPDH | PGAM4 |
| HIF-1 signaling pathway | 1.15 | 5.9405 | | ALDOC | PFKL | PGM1 |
| | E-06 | | | GPI | PFKP | TALDO1 |
| | | | | ALDOA | GAPDH | PGK1 |
| | | | | ALDOC | GNPDA1 | PGAM1 |
| Pentose phosphate pathway | 4.51 | 9.3455 | | ENO1 | GPI | PGK1 |
| | E-10 | | | ENO2 | PFKL | TPI1 |
| | | | | ALDOA | GPI | PGK1 |
| | | | | ALDOC | GYS1 | PGM1 |
| REACTOME Pathways | 2.39 | 8.6215 | | CHST2 | HAS2 | SLC2A1 |
| | E-09 | | | ENO1 | PFKL | TALDO1 |
| | | | | ENO2 | PFKP | TPI1 |
| | | | | GAPDH | PGAM1 | XYLT2 |
| | | | | GNPDA1 | | |
| | | | | ALDOA | ENO2 | PGAM1 |
| Gluconeogenesis | 4.18 | 8.3785 | | ALDOC | GAPDH | PGK1 |
| | E-09 | | | ENO1 | GPI | TPI1 |
| | | | | ALDOA | GAPDH | PFKP |
| Glucose metabolism | 8.59 | 8.0658 | | ALDOC | GNPDA1 | PGAM1 |
| | E-09 | | | ENO1 | GPI | PGK1 |
| | | | | ENO2 | PFKL | TPI1 |
| | | | | ADH5 | GNPDA1 | PFKP |
| Metabolism | 3.28 | 4.48433 | | AIMP2 | GPI | PGAM1 |
| | E-05 | | | ALDOA | GYS1 | PGK1 |
| | | | | ALDOC | HAS2 | PGM1 |
| | | | | ANGPTL4 | HILPDA | PSMC2 |
| | | | | BCKDK | HSD17B10 | SEPHS2 |
| | | | | CA12 | INSIG2 | SLC16A3 |
| | | | | CACNB3 | LARS | SLC2A1 |
| | | | | CHST2 | LDHA | SLC3A2 |

| | | | | | | |
|----------------------|---|--------------|---|--|---|---|
| | | | CNDP2 COX14 ENO1 ENO2 GAPDH GLTP | NEU1 NQO1 ODC1 PCYT2 PFKL XYLT2 | TALDO1 TPI1 TXNRD1 VKORC1 XYLT2 | |
| Wiki Pathways | Pathways in clear cell renal cell carcinoma | 1.01 E-13 | 12.9958 | ALDOA ALDOC ENO1 ENO2 GAPDH GPI | LDHA PFKL PFKP PGK1 PGM1 | PLOD2 SLC2A1 SQSTM1 TPI1 VEGFA |
| | Glycolysis and Gluconeogenesis | 1.48 E-13 | 12.8290 | ALDOA ALDOC ENO1 ENO2 GAPDH | GPI LDHA PFKL PFKP | PGAM1 PGK1 SLC2A1 TPI1 |
| | Cori Cycle | 2.81 E-12 | 11.5512 | GAPDH GPI LDHA | PFKP PGAM1 PGK1 | SLC2A1 TALDO1 TPI1 |
| | Metabolic reprogramming in colon cancer | 2.96 E-09 | 8.5287 | ENO1 GAPDH GPI LDHA | PFKL PGAM1 PGK1 | SLC16A3 SLC2A1 TALDO1 |
| | Photodynamic therapy-induced HIF-1 survival signaling | 2.51 E-08 | 7.6000 | BNIP3 BNIP3L EGLN1 | LDHA PFKL PGK1 | SERpine1 SLC2A1 VEGFA |
| | Factor: Churchill; motif: CGGGNN | 3.51 E-05 | 4.4548 | N=135 | | |
| | Factor: Churchill; motif: CGGGNN; match class: 0 | 3.51 E-05 | 4.4548 | N=135 | | |
| Transcription Factor | Factor: HIF1A; motif: NNACGTGCNN; match class: 0 | 3.81 E-05 | 4.4195 | ALDOA BCKDK BNIP3 BNIP3L C11ORF98 C4ORF3 CA12 CACNB3 CCT6A DDX21 DDX41 ENO1 ENO2 ERO1A FUT11 | GAPDH HAS2 HILPDA KCTD11 LDHA MAPK7 METTL26 MOSPD3 NAB2 NOP56 NPM3 OSMR P4HA2 PFKL PFKP | PLXNA3 PPP1R3G PRMT6 PTPRF RSAD1 SEPHS2 SLC16A3 SMIM3 STAT1 STC1 TPI1 VEGFA VKORC1 WDR54 |
| | Factor: HIF1A; motif: NNACGTGCNN | 3.81 E-05 | 4.4195 | ALDOA BCKDK BNIP3 BNIP3L C11ORF98 C4ORF3 CA12 CACNB3 CCT6A DDX21 DDX41 ENO1 ENO2 ERO1A FUT11 | GAPDH HAS2 HILPDA KCTD11 LDHA MAPK7 METTL26 MOSPD3 NAB2 NOP56 NPM3 OSMR P4HA2 PFKL PFKP | PLXNA3 PPP1R3G PRMT6 PTPRF RSAD1 SEPHS2 SLC16A3 SMIM3 STAT1 STC1 TPI1 VEGFA VKORC1 WDR54 |

| | | | | |
|------------------------|--|--------------|--------|--|
| | Factor: HIF1; motif: GNNKACGTGCGNN; match class: 0 | 4.17 E-05 | 4.3796 | n = 56 |
| miRNA Sites | hsa-miR-331-3p | 0.0182 | 1.7394 | APBB1 APOL6 DDX21 FUT11 GAPDH GPI HSPD1 LARS LDHA MARCKSL1 NOP2 PFKL PGAM1 TPI1 |
| Human Protein Atlas | urinary bladder; urothelial cells [Approved, Low] | 0.0313 | 1.5042 | n = 62 |

S8 Table. Top five g:Profiler results for each category from the analysis of 154 genes differentially expressed in three control fibroblast lines cultured at hypoxia compared to the same three control fibroblast lines cultured at normoxia. Analysis was performed using the default settings and selecting the Ensembl ID with the most annotations for each gene name. The p-value cut-off was 0.05 after g:SCS significance adjustment. If number of significant genes in g:Profiler term is greater than 50, n is shown; full lists are available upon request.